Liaoyuan Pharmaceutical

What Liaoyuan Pharmaceutical does

Zhejiang Liaoyuan Pharmaceutical Co., Ltd. is a cGMP-certified Chinese manufacturer of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, headquartered in Linhai City, Zhejiang Province. Founded in 1994 as Linhai City Liaoyuan Chemical Co., Ltd. and renamed in March 2014, the company operates a 136,000-square-meter manufacturing facility with a total investment of RMB 200 million and a workforce of over 500, approximately 35% of whom are senior managerial and technical personnel. Liaoyuan focuses on three therapeutic areas — anticoagulants (Clopidogrel bisulfate, Ticlopidine hydrochloride, Rivaroxaban, Apixaban, Dabigatran etexilate), antidepressants (Mirtazapine, Duloxetine hydrochloride), and cardiovascular drugs (Ivabradine hydrochloride, plus intermediates for Verapamil and Denopamine) — and is positioned as a well-known international manufacturer of thiophene derivatives, a specialty chemistry class central to clopidogrel synthesis.

The company monetizes through direct B2B sales of APIs and intermediates to global pharmaceutical manufacturers, distributed via a dedicated international trade department with named account managers covering Europe, the United States, Japan, India, and South America. Revenue mechanics are quote-based with no public pricing disclosure, and pricing models are characterized as one-time license arrangements. The company maintains an unusually broad regulatory footprint for a mid-sized Chinese manufacturer, including EU GMP, CEP certifications for multiple substances, US DMF registrations with the FDA, JP GMP and PMDA certifications, ISO 9001 and ISO 14001, and a long-term COS from EDQM. It also holds 5 granted patents and operates a provincial high-tech R&D center.

Corporate ownership has shifted meaningfully over time: Liaoyuan listed on the New Third Board (NEEQ: 831271) in October 2014, became a controlled subsidiary of Ningbo Menovo Pharmaceutical Co., Ltd. (宁波美诺华药业股份有限公司) in 2017, and joined Jemincare Group at the end of 2022. The company has stated a long-term prospect goal of reaching RMB 1 billion in annual turnover within 3-5 years, supported by an expanding pipeline that includes next-generation anticoagulants (Rivaroxaban, Apixaban, Dabigatran etexilate), CNS APIs (Safinamide), and development-stage intermediates for Ticagrelor and Canagliflozin.

Name

Liaoyuan Pharmaceutical

Legal name

Zhejiang Liaoyuan Pharmaceutical Co., Ltd.

Website

https://liaoyuan.com.cn

Company type

Public

Founded year

1994

Operating status

Operating

Headcount range

251–500 employees

Short description

Zhejiang Liaoyuan Pharmaceutical Co., Ltd. is a cGMP-certified Chinese manufacturer of active pharmaceutical ingredients and intermediates for anticoagulants, antidepressants, and cardiovascular drugs, serving global pharmaceutical companies across Europe, the US, Japan, India, and South America. It is a controlled subsidiary of Ningbo Menovo and member of Jemincare Group.

Ownership category

akta.pro rank

Product category

Pharmaceutical Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Pharmaceutical API manufacturing
• Pharmaceutical intermediates
• Active pharmaceutical ingredients
• CGMP contract manufacturing
• Thiophene derivatives

Headquarters

HQ city

Linhai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Manufacturing and Sales: Manufactures and sells Active Pharmaceutical Ingredients (APIs) including Clopidogrel bisulfate, Ticlopidine hydrochloride, Mirtazapine, and cardiovascular drugs. Revenue generated through direct B2B sales to pharmaceutical companies globally.
2. Pharmaceutical Intermediates: Produces and sells pharmaceutical intermediates for anticoagulants, antidepressants, and cardiovascular drugs. Key intermediates include Clopidogrel intermediates, Duloxetine intermediates, and Mirtazapine intermediates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Zhejiang Liaoyuan Pharmaceutical Co., Ltd. manufactures and sells cGMP-certified Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates, focusing on anticoagulants (Clopidogrel bisulfate, Ticlopidine hydrochloride, Rivaroxaban, Apixaban, Dabigatran etexilate), antidepressants (Mirtazapine, Duloxetine hydrochloride), and cardiovascular drugs (Ivabradine hydrochloride). The company is recognized internationally as a leading manufacturer of thiophene derivatives and sells its products directly to global pharmaceutical manufacturers in Europe, the United States, Japan, India, and South America.

Product overview

Liaoyuan Pharmaceutical (浙江燎原药业有限公司) is a cGMP-certified pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. The company operates a single unified product portfolio focused on three therapeutic areas: anticoagulants (Clopidogrel bisulfate, Ticlopidine hydrochloride, Rivaroxaban, Apixaban, Dabigatran etexilate), antidepressants (Mirtazapine, Duloxetine hydrochloride), and cardiovascular drugs (Ivabradine hydrochloride, Verapamil, Denopamine intermediates). Liaoyuan is particularly recognized as a leading manufacturer of thiophene derivatives in the international market. The company also produces a range of pharmaceutical intermediates for various drug categories including antipsychotics (Lurasidone, Asenapine), antiplatelet agents (Prasugrel, Ticagrelor), and other therapeutic compounds. Key API products include Ticlopidine hydrochloride, Mirtazapine, Clopidogrel bisulfate, Duloxetine hydrochloride, and Rebamipide, with various certifications including EU GMP, CEP, JP GMP, and US DMF. The company has established itself as a qualified supplier to global pharmaceutical markets, particularly in Europe, Japan, and the United States.

Differentiator

Problem solved

Functional benefit

Products and services

• Clopidogrel bisulfate Antiplatelet agent API used to prevent heart attacks and strokes. CEP/US DMF certified. Liaoyuan is recognized as a leading thiophene derivatives manufacturer with this product.
• Ticlopidine hydrochloride
• Mirtazapine
• Duloxetine hydrochloride
• Rebamipide
• Ivabradine hydrochloride
• Clopidogrel intermediates
• Duloxetine intermediates
• Mirtazapine intermediates
• Dabigatran etexilate intermediates
• Lurasidone intermediates
• Asenapine intermediates
• Prasugrel intermediates
• Ivabradine, Verapamil, Denopamine intermediates
• Drotaverine intermediates
• Bepotastine intermediates
• Moxifloxacin intermediate

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Ningbo Menovo Pharmaceutical Co., Ltd. (宁波美诺华药业股份有限公司)coreStrategic or Co-development PartnerIn 2017, Liaoyuan became a controlled subsidiary of listed company Ningbo Menovo Pharmaceutical Co., Ltd., gaining access to broader pharmaceutical industry resources and capital market support.
• Jemincare GroupcoreStrategic or Co-development PartnerLiaoyuan became a member of Jemincare Group, integrating into a larger pharmaceutical ecosystem with shared resources and market access.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Apeloa Pharmaceutical: Chinese API and intermediate manufacturer with strong global distribution and cGMP certifications. Comparable business model as a B2B API supplier with broad therapeutic coverage and similar international trade footprint.
• Divi's Laboratories: Indian-headquartered API and intermediates manufacturer with strong European and US regulatory footprint. Comparable as a custom-synthesis and generic API specialist serving global pharma customers.
• Zhejiang Hisun Pharmaceutical: Major Chinese API and intermediates producer listed on Shanghai Stock Exchange. Comparable as a large-scale Chinese API manufacturer with FDA/EDQM approvals, anti-infective and cardiovascular portfolios, and global B2B distribution.
• Ningbo Menovo Pharmaceutical: Parent company of Liaoyuan since 2017 and a Chinese listed API manufacturer. Directly comparable as a sister API manufacturer within the same corporate group with overlapping cardiovascular and CNS API portfolios.
• Zhejiang Huahai Pharmaceutical: One of China's largest API and finished-dose generic manufacturers, also Zhejiang-based, exporting globally with strong FDA/EMA presence. Directly comparable as a Chinese specialty API producer with international regulatory certifications and cardiovascular focus (notably antihypertensives like Losartan).
• Zhejiang Medicine Co., Ltd. Zhejiang-based pharmaceutical and API manufacturer with global export orientation. Comparable as a regional Chinese API peer with similar certifications and chemical-manufacturing heritage.

Broad incumbents

• Teva Pharmaceutical Industries (API Division): Operates one of the largest API manufacturing networks globally through its Teva API business. Comparable as a high-volume generic API producer with broad therapeutic coverage, though at vastly greater scale and with finished-dose integration.
• Dr. Reddy's Laboratories: Global integrated pharmaceutical company with a substantial API division. Comparable as a high-volume API manufacturer supplying regulated markets, especially in cardiovascular and CNS categories.
• Aurobindo Pharma: One of the world's largest generic API manufacturers headquartered in India. Comparable as a global generic API supplier with extensive US FDA filings and cardiovascular/anticoagulant exposure, but at significantly greater scale.

Others

• Jemincare Group: Parent group of Liaoyuan since end-2022 and a diversified Chinese pharmaceutical group. Comparable as the corporate parent shaping Liaoyuan's strategic direction, capital allocation, and access to group-level customer relationships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liaoyuan Pharmaceutical